Celsion Corporation (NASDAQ:CLSN) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 616,155 shares, a decrease of 57.6% from the October 13th total of 1,453,427 shares. Approximately 5.7% of the company’s shares are short sold. Based on an average daily volume of 1,442,052 shares, the short-interest ratio is currently 0.4 days.
A hedge fund recently bought a new stake in Celsion Corporation stock. Sabby Management LLC acquired a new stake in shares of Celsion Corporation (NASDAQ:CLSN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned approximately 1.30% of Celsion Corporation as of its most recent filing with the Securities and Exchange Commission. 5.66% of the stock is owned by institutional investors and hedge funds.
Shares of Celsion Corporation (NASDAQ CLSN) opened at $2.00 on Monday. Celsion Corporation has a 12 month low of $1.24 and a 12 month high of $12.88.
Several brokerages recently issued reports on CLSN. Maxim Group reiterated a “hold” rating on shares of Celsion Corporation in a research note on Tuesday, August 15th. Zacks Investment Research lowered shares of Celsion Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, ValuEngine upgraded shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $12.63.
COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/11/13/celsion-corporation-clsn-short-interest-down-57-6-in-october.html.
About Celsion Corporation
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.